Fact CheckerSign in

NCT06374264Enrolling by invitation

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

A Single Arm, Prospective, Multi-Center, Feasibility Study to Evaluate the Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder (NMOSD) Who Have an Impaired Gait

Source: ClinicalTrials.gov · Last updated 6 Jul 2026

Brief summary (registry, in English)

The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
30 (estimated)
First submitted
10 Apr 2024
Start date
12 Nov 2024
Primary completion date
30 Sept 2026
Lead sponsor
MedRhythms, Inc.
NCT number
NCT06374264

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 12 Nov 2024 to the primary completion date, 30 Sept 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Initiated physical therapy for lower limb in the past 4 weeks or anticipated to start due to safety concerns (e.g., falls).
  • Treatment with a gait-based investigational intervention within the last 3 months. Enrollment in observational studies is allowed.

Other illness

  • Significant co-morbid medical or neurological disease or injury, or treatment for such conditions that currently affects, or has potential to affect, participant gait for safety during participation in the study as determined by the investigator.
  • Initiation, change, or discontinuation of disease-modifying therapy in the past 3 months known to affect gait (e.g., dalfampridine, corticosteroid, medications for spasticity).
  • Severe hearing impairment with or without the use of hearing aids, such that the participant cannot hear the rhythmic music stimulus consistently, as determined by participant and investigator.

Other

  • Unable or unwilling to comply with study protocol.
  • People who become pregnant or are pregnant (due to expected changes in gait patterns).
  • Unable to safely participate in protocol-defined walking sessions of 30-minute duration as determined by the investigator.
  • Has an external lower limb prosthetic ("artificial limb").
  • Requires at least one seated rest during the T25FWT.
  • Recent NMOSD relapse (last 3 months) and/or hospitalization.
  • Vulnerable populations as deemed inappropriate for study by investigator. For this protocol, vulnerable persons are considered to be those who are relatively (or absolutely) incapable of protecting their own interests.

Who the study is looking for

  • Age 18-70 years of age (inclusive).
  • Able to read and/or understand English.
  • Meets revised diagnostic criteria for NMOSD proposed by the International Panel for NMO Diagnosis (IPND) in 2015.
  • Past clinical history of Transverse Myelitis as seen on imaging or as determined by clinical review by the investigator.
  • Demonstrates an observable gait deficit resulting from a diagnosis of NMOSD as determined by the Investigator or medical history review.
  • Currently able to walk at a speed greater or equal to 0.4 m/s, but less than 1.5 m/s, as determined by walking speed during a Timed 25-Foot Walk Test (T25FWT) (cane(s), walking stick(s), crutch(es), wheeled walker, external functional neuromuscular stimulator(s), and ankle foot orthosis allowed).
    • Note: if assistive devices are planned to be used during the Intervention Phase walking sessions, they should be used during the Screening, Baseline, and Closing visit gait assessments as well.
  • Has a reciprocal gait pattern.
    • Note: a non-reciprocal gait pattern is defined as a 3-point step pattern. Participants must have a 2-point step pattern to qualify. Asymmetry seen in gait is acceptable.
  • Ability and willingness to provide Informed Consent.

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Sheperd Center
Coordinator of this site? Confirm its status
AtlantaUnited StatesUnknown status
Massachusetts General Hospital
Coordinator of this site? Confirm its status
BostonUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.